What does Eupraxia Pharmaceuticals Inc. do?

Eupraxia Pharmaceuticals Inc. (EPRX.TO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is EPRX.TO's market cap?

Eupraxia Pharmaceuticals Inc. (EPRX.TO) has a market capitalization of approximately $369.4 million, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does EPRX.TO pay a dividend?

No — Eupraxia Pharmaceuticals Inc. (EPRX.TO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is EPRX.TO profitable?

Eupraxia Pharmaceuticals Inc. (EPRX.TO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

EPRX.TO

Eupraxia Pharmaceuticals Inc.

TSX·Biotechnology · Healthcare

C$10.28C$0.08+0.78%

Market capC$369.44M·Market closed·Aug 26 8:00 PM UTC

Price Chart

C$10.28+C$0.08 (+0.78%)today

+223.27%CAGR +26.45%

Select date range

FromTo

Mar 9, 2021Aug 27, 2021 → Aug 27, 2026· 5.0 yrsAug 27, 2026

Key Metrics

EPRX.TO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateNov 3

Last Report DateAug 11

Reported vs Estimate−C$0.22 vs −C$0.32

Earnings Surprise+30.6%

FinancialsFinancials Tab

Revenue$0.00

Net Income−$49.89M

Net Margin—

Operating Cash Flow−$35.84M

Capital Expenditures$730.62K

Free Cash Flow−$36.57M

Return on Equity−38.1%

Return on Invested Capital−13.4%

Net Cash$131.60M

Analyst Estimates

PRO

Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.

Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for EPRX.TO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how EPRX.TO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EPRX.TO and 80,000+ other tickers.

About Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an…

CEO: James A. Helliwell
Sector: Healthcare
Industry: Biotechnology
Exchange: TSX
Employees: 49
Website: www.eupraxiapharma.com

Peers

Fennec Pharmaceuticals Inc.

Latest News

News Tab

No recent news available.

Frequently Asked Questions About EPRX.TO

What does Eupraxia Pharmaceuticals Inc. do?: Eupraxia Pharmaceuticals Inc. (EPRX.TO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is EPRX.TO's market cap?: Eupraxia Pharmaceuticals Inc. (EPRX.TO) has a market capitalization of approximately $369.4 million, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does EPRX.TO pay a dividend?: No — Eupraxia Pharmaceuticals Inc. (EPRX.TO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is EPRX.TO profitable?: Eupraxia Pharmaceuticals Inc. (EPRX.TO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.